Featured Research Search Results
Study of a New Targeted Therapy Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer
Clinicaltrials.gov identifier:
NCT06841354
Treatment
Treatment study for people with metastatic, triple-negative breast cancer
Treating Advanced Cancers with DNA-Repair Mutations Using MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
Clinicaltrials.gov identifier:
NCT06545942
Treatment
Treatment study for people with advanced or metastatic cancers
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT05932862
Treatment
Treatment study for people with advanced solid tumors
Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
Clinicaltrials.gov identifier:
NCT06380751
Treatment
Treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
An Online Program to Help Asian American Breast Cancer Survivors Manage Pain and Depression
Clinicaltrials.gov identifier:
NCT06085313
Quality of Life
An online program to help Asian American breast cancer survivors manage pain and depression
Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs
Clinicaltrials.gov identifier:
NCT06167317
Treatment
Treatment study for people with advanced or metastatic solid tumors
HEAL-ABC Study: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer
Clinicaltrials.gov identifier:
NCT06748222
Quality of Life
Quality of life study for young breast cancer survivors who have symptoms associated with depression
Sexual Health and Rehabilitation Online (SHAREonline): An Educational Intervention for Young Women after Cancer
Clinicaltrials.gov identifier:
NCT06458049
Quality of Life
An online study comparing two educational interventions for female cancer survivors experiencing sexual health changes
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib
Clinicaltrials.gov identifier:
NCT06488378
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer
Clinicaltrials.gov identifier:
NCT06401421
Treatment
Biomarker study for people with early-stage breast cancer
Testing a Shorter Course of Chemo- and Immunotherapy for People With Early-Stage Triple-Negative Breast Cancer
Clinicaltrials.gov identifier:
NCT05929768
Treatment
Treatment study for early-stage triple-negative breast cancer
Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation
Clinicaltrials.gov identifier:
NCT04090567
Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
New Treatment in People with Triple Negative Breast Cancer or Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT06022029
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
ShareForCures®: Susan G. Komen's People-Powered, Data-Driven Breast Cancer Research Registry
Clinicaltrials.gov identifier:
NCT05654246
Surveys, Registries, Interviews
Registry for anyone diagnosed with breast cancer
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
Clinicaltrials.gov identifier:
NCT05417594
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
WISDOM Study: Women Informed to Screen Depending on Measures of Risk
Clinicaltrials.gov identifier:
NCT02620852
Prevention
Genetic testing and breast cancer screening
Observing People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )
Clinicaltrials.gov identifier:
NCT01443468
Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families
A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)
Clinicaltrials.gov identifier:
NCT03729115
Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor
Sponsored By
